IRINOTECAN HYDROCHLORIDE | A206935 | INGENUS PHARMACEUTICALS LLC
No patent or exclusivity listings for this strength.
INGENUS PHARMS LLC became the applicant for irinotecan hydrochloride (NDA 206935, strength 001), replacing NOVAST LABS.
Old: NOVAST LABS
New: INGENUS PHARMS LLC
INGENUS PHARMACEUTICALS LLC replaced NOVAST LABORATORIES LTD as the applicant for irinotecan hydrochloride NDA 206935.
Old: NOVAST LABORATORIES LTD
New: INGENUS PHARMACEUTICALS LLC
Ingenus Pharms LLC became the applicant of record for Irinotecan Hydrochloride (NDA 206935, supplement 002), replacing Novast Labs.
Old: NOVAST LABS
New: INGENUS PHARMS LLC
INGENUS PHARMACEUTICALS LLC acquired or assumed the ANDA for irinotecan hydrochloride (NDA 206935, supplement 002) from NOVAST LABORATORIES LTD.
Old: NOVAST LABORATORIES LTD
New: INGENUS PHARMACEUTICALS LLC